A61K 38/1716
Amyloid plaque core protein
Official title: {Amyloid plaque core protein}
A61K38/1716 (Amyloid plaque core protein) appears on 48 US grants and 123 published applications in this corpus.
Search patents in A61K- Granted patents
- 48
- Published applications
- 123
- Assignees
- 96
- Inventors
- 265
- Latest grant
- 1 Jul 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2005 | 0 | 1 |
| 2006 | 0 | 0 |
| 2007 | 0 | 1 |
| 2008 | 0 | 4 |
| 2009 | 2 | 2 |
| 2010 | 1 | 8 |
| 2011 | 1 | 6 |
| 2012 | 3 | 3 |
| 2013 | 0 | 5 |
| 2014 | 1 | 5 |
| 2015 | 3 | 9 |
| 2016 | 4 | 7 |
| 2017 | 5 | 3 |
| 2018 | 3 | 11 |
| 2019 | 3 | 8 |
| 2020 | 6 | 5 |
| 2021 | 2 | 7 |
| 2022 | 2 | 12 |
| 2023 | 3 | 8 |
| 2024 | 6 | 4 |
| 2025 | 3 | 9 |
| 2026 | 0 | 5 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Antibodies to amyloid beta1 Jul 2025US 12,344,664 B2MedImmune, LLC
- Chimeric protein in the treatment of amyloidosis6 May 2025US 12,291,552 B2Centre National de la Recherche Scientifique (CNRS)
- Etch selectivity control in atomic layer etching22 Apr 2025US 12,280,091 B2Lam Research Corporation
- SAP FC fusion proteins and methods of use10 Dec 2024US 12,161,692 B2Attralus, Inc.
- Antibodies to amyloid beta24 Sep 2024US 12,098,191 B2MedImmune, LLC
- Polypeptide combination dosage regimens24 Sep 2026US 2026/0284148 A1
- Inhibitory Peptides for the Diagnostic and/or Treatment of Tauopathies27 Aug 2026US 2026/0248877 A1École des Hautes Études en Santé Publique
- Treating alzheimer's disease11 Jun 2026US 2026/0159559 A1Ramot at Tel-Aviv University Ltd.
- Structure-based design of a novel class of drugs for neurodegenerative disease22 Jan 2026US 2026/0021092 A1The Regents of the University of California
- Strategies For Knock-Ins At APLP2 Safe Harbor Sites22 Jan 2026US 2026/0021141 A1EmendoBio Inc.
Most cited
By later US patents
- Encapsulated amyloid-beta peptides33US 7,618,944 B2Intezyne Technologies, Inc. · 2009
- Targeting immunotherapy for amyloidosis8US 10,046,050 B2University of Tenessee Research Foundation · 2018
- Antibodies to amyloid beta7US 10,662,239 B2MedImmune, LLC · 2020
- Targeting immunotherapy for amyloidosis6US 10,213,506 B2University of Tennessee Research Foundation · 2019
- Conjoint therapy for treating fibrotic diseases5US 8,247,370 B2Promedior, Inc. · 2012